[go: up one dir, main page]

Vieira et al., 2013 - Google Patents

SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor …

Vieira et al., 2013

Document ID
5542495075594893625
Author
Vieira M
Wallenstein G
Bradley J
Gruben D
Koncz T
Zwillich S
Jansen J
Publication year
Publication venue
Annals of the Rheumatic Diseases

External Links

Snippet

Background Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Objectives To compare the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) relative to biologic disease-modifying antirheumatic drugs …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Yamanaka et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
Krieckaert et al. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
Mease et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
AlGhamdi et al. Treatment of generalized vitiligo with anti-TNF-a agents
Takeuchi et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
Chaabo et al. Rheumatoid arthritis—anti-TNF
AU2023257666A1 (en) Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody
Genovese et al. SAT0117 sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: Relationship between eular responses and change from baseline of selected clinical parameters
Vieira et al. SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor Inhibitors-A Network Meta-Analysis
Kao et al. Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan
Rossini et al. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Cimmino et al. SAT0114 Effects Of Tocilizumab (TCZ) in Combination with Non-Biologic Dmards in the Inhibition of Progression of Synovitis, Bone Marrow Edema and Erosions Evaluated by Extremity-Dedicated Magnetic Resonance Imaging (MRI) In Rheumatoid Arthritis (RA)
Hirao et al. SAT0113 Intense Repression of Serum Oxidative Stress Marker in Rheumatoid Arthritis Cases Treated with Tocilizumab: Cross Sectional and Longitudinal Evaluation
Van Den Broek et al. SAT0116 Safety and Efficacy of Ara290, a Non-Hematopoietic Erythropoietin Derived Peptide, in a 4 Weeks Phase II Open Label Trial in Patients with Active Rheumatoid Arthritis.
Silva-Fernandez et al. OP0029 The risk of serious infections in patients receiving rituximab for rheumatoid arthritis
Garcia et al. AB0334 COST-EFECTIVENESS OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN THE REAL WORL PRACTICE
Herold et al. FRI0172 Commonplace Though not Approved–Monotherapy with Biologics. Data from the Austrian Bioreg Registry
Morimoto et al. FRI0129 the BTK inhibitor, fenebrutinib, effectively modulates B and myeloid cell biology in rheumatoid arthritis patients
Alten et al. FRI0245 Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world action study
Ojeda et al. AB0381 Change is good, but what is better? retrospective study in clinical practice first switch with different biological therapies in rheumatoid arthritis
Sheng-Xiao et al. SAT0181 low dose interleukin-2 combined with tocilizumab selectively increases regulatory t cells helping refractory rheumatoid arthritis patients achieve remission more rapidly
Klein et al. SAT0490 Matched Controlled Surveillance of Tocilizumab Treatment for Polyarticular Juvenile Idiopathic Arthritis–An Interim Analysis
Avdeeva et al. POS0611 THE EFFECT OF RITUXIMAB BIOSIMILAR THERAPY ON THE EXPRESSION OF INTERFERON-STIMULATED GENES (“INTERFERON SIGNATURE”) IN PATIENTS WITH RHEUMATOID ARTHRITIS
Antony et al. AB0235 RITUXIMAB (BIOSIMILAR) IN RHEUMATOID ARTHRITIS: CLINICAL & IMMUNOLOGICAL RESPONSE TO VARYING DOSES-EXPERIENCES FROM A TERTIARY CARE CENTER IN SOUTH INDIA
Gridneva et al. FRI0151 THE RELATIONSHIP BETWEEN THE EFFECTIVENESS OF METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) AND MTX POLYGLUTAMATES LEVELS (MTXPGS) IN RED BLOOD CELLS BY TANDEM CHROMATOMASS SPECTROMETRY (PILOT STUDY)